Damora Therapeutics Quarterly Balance Sheet
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics financial position
As of Jun 30, 2026, Damora Therapeutics reported total assets of $543.6 million, up 3870.8% from a year earlier against total liabilities of $27.6 million. Shareholders' equity stood at $516.1 million, or 94.9% of assets. The company held $540.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 19.73, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 540.51M | 532.90M | 257.62M | 7.61M | 10.21M | 11.94M | 14.18M | 19.68M | 22.86M | 21.09M | 21.46M | 23.08M |
| Short-Term Investments | — | — | — | — | — | — | — | — | — | 6.08M | 11.69M | 21.10M |
| Total Current Assets | 543.59M | 535.41M | 260.42M | 9.79M | 13.03M | 14.92M | 16.84M | 21.18M | 25.17M | 30.54M | 36.77M | 47.05M |
| Property, Plant & Equipment | — | — | 36.00K | 41.00K | 47.00K | 52.00K | 57.00K | 62.00K | 67.00K | 73.00K | 78.00K | 125.00K |
| Total Assets | 543.64M | 535.44M | 260.53M | 10.74M | 13.69M | 15.37M | 17.13M | 23.38M | 27.30M | 32.48M | 38.23M | 50.05M |
| Accounts Payable | 3.48M | 819.00K | 444.00K | 520.00K | 756.00K | 354.00K | 377.00K | 503.00K | 724.00K | 1.67M | 1.70M | 4.48M |
| Total Current Liabilities | 27.55M | 23.81M | 20.07M | 2.62M | 2.63M | 1.55M | 1.20M | 2.44M | 3.71M | 4.32M | 5.83M | 12.55M |
| Total Liabilities | 27.58M | 23.84M | 20.15M | 2.73M | 2.74M | 1.66M | 1.30M | 2.44M | 3.71M | 4.32M | 5.90M | 12.67M |
| Shareholders' Equity | 516.06M | 511.60M | 240.38M | 8.01M | 10.95M | 13.71M | 15.83M | 20.93M | 23.59M | 28.16M | 32.33M | 37.38M |
| Retained Earnings | -546.32M | -515.15M | -487.36M | -286.63M | -283.49M | -280.06M | -277.52M | -270.78M | -266.90M | -261.56M | -256.08M | -249.61M |
| Net Cash (Debt) | 540.51M | 532.90M | 257.62M | 7.61M | 10.21M | 11.94M | 14.18M | 19.68M | 22.86M | 27.17M | 33.15M | 44.18M |
| Shares Outstanding | 61.73M | 60.30M | 1.60M | 1.33M | 1.32M | 1.32M | 1.32M | 1.25M | 27.12M | 27.11M | 1.08M | 27.11M |
This table shows 12 quarterly periods of Damora Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a balance sheet?